OCT guided vs. COmplete pci in patieNts with sT segment elevation myocArdial infarCtion and mulTivessel disease: OCT-CONTACT RCT

医学 传统PCI 心脏病学 经皮冠状动脉介入治疗 心肌梗塞 内科学 狼牙棒 罪魁祸首 部分流量储备 随机对照试验 血运重建 临床终点 冠状动脉造影
作者
Mario Iannaccone,Ovidio De Filippo,Andrea Montabone,Giorgio Marengo,Ludovica Maltese,Fabrizio Ugo,Giorgio Quadri,Maro MENNUNI,Gioel Gabrio Secco,Vittorio Taglialatela,Sebastian Cinconze,Claudio Moretti,Alessandra Truffa,Alfonso Gambino,Giacomo Boccuzzi,Vincenzo Infantino,Federico Conrotto,Alessandro Lupi,Ferdinando Varbella,Giuseppe Patti
出处
期刊:Minerva cardiology and angiology [Edizioni Minerva Medica]
卷期号:71 (4) 被引量:4
标识
DOI:10.23736/s2724-5683.22.06144-0
摘要

In patients with ST-segment elevation myocardial infarction (STEMI), percutaneous coronary intervention (PCI) of the culprit lesion significantly reduces the risk of cardiovascular death. However, the management of non-culprit lesions in patients with the multivessel disease remains a matter of debate in this setting. It's still unclear if a morphological OCT-guided approach, identifying coronary plaque instability, may provide a more specific treatment compared with a standard angiographic/functional approach.OCT-Contact is a prospective, multicenter, open-label, non-inferiority randomized controlled trial. Patients with STEMI with successful primary PCI of the culprit lesion will be enrolled after the index PCI. Patients will be deemed eligible if a critical coronary lesion other than the culprit (associated with a diameter of stenosis ≥50%) will be identified during the index angiography. Patients will be randomized in a 1:1 fashion to OCT-guided PCI of non-culprit lesions (Group A) vs. complete PCI (Group B). PCI in group A will be undertaken according to criteria of plaque vulnerability, while in group B the use of fractional flow reserve will be left at the operators' discretion. Major-adverse cardiovascular events (MACE) are a composite of all-cause mortality, non-fatal myocardial infarction (MI) (excluding peri-procedural MI), unplanned revascularization, and NYHA IV heart failure) will be the primary efficacy outcome. Single components of MACE along with cardiovascular mortality will be the secondary endpoints. . Safety endpoints will embrace worsening of renal failure, procedural complications, and bleedings. Patients will be followed for 24 months after randomization.A sample size of 406 patients (203 per group) is required to provide the analysis an 80% power to detect a non-inferiority in the primary endpoint with an alpha error set at 0.05 and a non-inferiority limit of 4%.A morphological OCT-guided approach may be a more specific treatment compared with the standard angiographic/functional approach in non-culprit lesions of STEMI patients.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
windows发布了新的文献求助10
刚刚
标致雪糕发布了新的文献求助10
1秒前
情怀的应助被1230采纳,获得10
2秒前
2秒前
勤容完成签到,获得积分20
2秒前
领导范儿的应助被LightningFast采纳,获得10
3秒前
小翟发布了新的文献求助10
3秒前
3秒前
木头人的应助被宇an采纳,获得10
4秒前
TiAmo完成签到,获得积分10
5秒前
molihuakai的应助被木木采纳,获得10
5秒前
从容的板凳完成签到,获得积分10
5秒前
6秒前
狂野冷荷完成签到 ,获得积分10
6秒前
林狗发布了新的文献求助10
7秒前
畅快新之发布了新的文献求助10
7秒前
liuying6618发布了新的文献求助10
8秒前
8秒前
马克完成签到,获得积分10
8秒前
扬眉亮剑完成签到,获得积分10
9秒前
CarryLJR发布了新的文献求助10
9秒前
Dr.c发布了新的文献求助10
9秒前
9秒前
小二郎的应助被沐沐采纳,获得10
10秒前
10秒前
核桃发布了新的文献求助10
11秒前
慢慢完成签到 ,获得积分10
11秒前
11秒前
开朗平松完成签到 ,获得积分10
12秒前
12秒前
李爱国的应助被dorothy采纳,获得10
13秒前
木头人的应助被longlong采纳,获得10
13秒前
今夜有雨发布了新的文献求助10
13秒前
Marine吃苹果完成签到 ,获得积分10
13秒前
清新的南琴完成签到,获得积分10
14秒前
15秒前
甜美的穆发布了新的文献求助10
15秒前
勤容关注了科研通微信公众号
16秒前
vision0000发布了新的文献求助10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Rosenblum, Global Change Biology 800
Organizational Behavior 510
Management and the Arts 510
Convergent and bidirectional strategies towards the total synthesis of hemibrevetoxin B 300
Geschichtliche Grundbegriffe (GGB), Band 5: Pro–Soz 300
Die Religion in Geschichte und Gegenwart (RGG), 4. Auflage, Band 7: R–S 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 内科学 物理 有机化学 化学工程 生物化学 复合材料 光电子学 细胞生物学 心理学 量子力学 催化作用 物理化学 电极
热门帖子
关注 科研通微信公众号,转发送积分 7796364
求助须知:如何正确求助?哪些是违规求助? 9332098
关于积分的说明 20447542
捐赠科研通 7386737
什么是DOI,文献DOI怎么找? 3324973
关于科研通互助平台的介绍 2472291
邀请新用户注册赠送积分活动 2342129